news
Refeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
List view / Grid view
Informatics
podcasts
Overcoming obstacles in personalised medicine
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
article
AI paves the way for new immunotherapy targets
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
article
The paradox of data in precision medicine
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
news
New AI model may enable more targeted prostate cancer treatment
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
article
Bridging science and technology: a biotech CEO’s perspective
In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.
news
Proscia: advancing pathology AI development
Proscia has launched two new products which will help to accelerate discovery and development of new therapies and diagnostics.
news
The Pistoia Alliance: key findings on AI
Results from Pistoia Alliance’s Lab of the Future survey has shared important findings about the challenges life science companies face.
article
AI-driven drug discovery: insights from Cresset
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
article
Part four: an industry leader’s perspective on managing data quality
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
news
New network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
webinar
Overcoming critical challenges in AI-driven drug discovery
16 September 2024 | By Drug Target Review
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer…
news
Sino Biological and BioGeometry: advancing protein R&D
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.